New insider activity at Medpace Holdings ( (MEDP) ) has taken place on November 12, 2025.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Susan E. Burwig, the Executive Vice President of Operations at Medpace Holdings, recently sold 18,000 shares of the company’s stock. This transaction was valued at a substantial $10,890,000.
Recent Updates on MEDP stock
In the last 24 hours, Medpace Holdings has been in the spotlight due to several significant clinical study updates and analyst coverage. BMO Capital initiated coverage of Medpace with a Market Perform rating, citing the stock’s full valuation amidst a challenging biotech funding environment and potential macroeconomic volatility. Additionally, Medpace announced updates on multiple ongoing clinical studies, including collaborations with AVM Biotechnology and Telix Pharmaceuticals. These studies focus on innovative treatments for conditions such as lymphoid malignancies, acute respiratory distress syndrome, and advanced kidney cancer. The promising nature of these studies, particularly in the oncology sector, could enhance investor confidence and positively influence Medpace’s stock performance. The strategic partnerships and advancements in immunomodulatory therapies and targeted radiation treatments underscore Medpace’s commitment to pioneering new therapeutic options in the competitive healthcare landscape.
Spark’s Take on MEDP Stock
According to Spark, TipRanks’ AI Analyst, MEDP is a Outperform.
Medpace Holdings demonstrates strong financial performance and positive earnings call sentiment, which are the most significant factors driving the score. Technical analysis indicates strong momentum but also suggests caution due to overbought conditions. The high P/E ratio impacts the valuation score, reflecting potential overvaluation concerns.
To see Spark’s full report on MEDP stock, click here.
More about Medpace Holdings
YTD Price Performance: 80.07%
Average Trading Volume: 326,859
Technical Sentiment Signal: Buy
Current Market Cap: $16.91B